Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10147182 | 0.81 | POLB (0.40) | POLBTLR7LMNAHRH2ADRA1D | |
| SCHEMBL1301644 | 0.79 | PKM (0.40) | POLBTLR7LMNAHRH2ADRA1D | |
| SCHEMBL16321075 | 0.76 | POLB (0.44) | POLBTLR7LMNAHRH2ADRA1D | |
| SCHEMBL13980982 | 0.73 | ADORA2A (0.47) | POLBTLR7LMNAHRH2ADRA1D | |
| SCHEMBL18721825 | 0.70 | — | — | |
| SCHEMBL1302589 | 0.69 | TLR7 (0.41) | POLBTLR7LMNAHRH2ADRA1D | |
| SCHEMBL4817123 | 0.68 | TLR7 (0.67) | POLBTLR7LMNAHRH2ADRA1D | |
| SCHEMBL19553628 | 0.67 | POLB (0.55) | POLBKCNH2CHRNB2CHRNA4 | |
| SCHEMBL8465200 | 0.67 | ADORA2A (0.47) | LMNAADORA2ATGFBR1SMN1; SMN2CCNE1 | |
| SCHEMBL8465291 | 0.67 | ADORA2A (0.47) | LMNAADORA2ATGFBR1SMN1; SMN2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034336-B2 | Immunomodulators and immunomodulator conjugates | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034336-B2 | Immunomodulators and immunomodulator conjugates | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2015-05-19 | — | — | US | disclosed |
| US-20140212442-A1 | IMMUNOMODULATORS AND IMMUNOMODULATOR CONJUGATES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140212442-A1 | IMMUNOMODULATORS AND IMMUNOMODULATOR CONJUGATES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-07-31 | — | — | US | disclosed |
| US-8168802-B2 | Ring closing and related methods and intermediates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168802-B2 | Ring closing and related methods and intermediates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168802-B2 | Ring closing and related methods and intermediates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110269965-A1 | Ring Closing and Related Methods and Intermediates | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269965-A1 | Ring Closing and Related Methods and Intermediates | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269965-A1 | Ring Closing and Related Methods and Intermediates | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2009002-A1 | New process for the manufacture of 1H-imidazo [4,5-c]-quinoline ring systems | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2008-12-31 | — | — | EP | disclosed |
| EP-1863770-A2 | RING CLOSING AND RELATED METHODS AND INTERMEDIATES | Coley Pharmaceutical Group, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006121528-A2 | RING CLOSING AND RELATED METHODS AND INTERMEDIATES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269965-A1 | Ring Closing and Related Methods and Intermediates | CYP11B1, CYP11B2, CYP2F1 | POLB 369/4885TLR7 4832/4885LMNA 774/4885 |
| US-20140212442-A1 | IMMUNOMODULATORS AND IMMUNOMODULATOR CONJUGATES | CD40, CD47, FCGRT | POLB 3997/4885TLR7 124/4885LMNA 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.